Home › Funds › Cormorant Asset Management, LP › ARQT
Cormorant Asset Management, LP position in ARQT
ARCUTIS BIOTHERAPEUTICS INC · Health Care
Cormorant Asset Management, LP reported holding 175,000 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$4.6M, representing 0.24% of its reported portfolio and ranking #40 among its reported holdings. Cormorant Asset Management, LP has disclosed ARQT holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's ARQT position evolved
Cormorant Asset Management, LP first disclosed a stake in ARQT in Q1 2024 at 2,125,000 shares (US$21.1M). The position peaked in Q4 2024 at 1,825,000 shares, worth US$25.4M. Across 10 filings, Cormorant Asset Management, LP increased the stake 1 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 175,000 shares valued at US$4.6M — a reduction of -275,000 shares quarter over quarter.. Notable position changes include a 26% trim in Q1 2025 (shares fell 10% over the following quarter), a 35% trim in Q4 2025 (shares fell 19% over the following quarter), a 61% trim in Q2 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 2.12M | $21.06M | New |
| Q2 2024 | 2.52M | $23.48M | Add |
| Q3 2024 | 2.33M | $21.62M | Reduce |
| Q4 2024 | 1.82M | $25.42M | Reduce |
| Q1 2025 | 1.35M | $21.11M | Reduce |
| Q2 2025 | 1.00M | $14.02M | Reduce |
| Q3 2025 | 775.00K | $14.61M | Reduce |
| Q4 2025 | 500.00K | $14.52M | Reduce |
| Q1 2026 | 450.00K | $10.60M | Reduce |
| Q2 2026 | 175.00K | $4.59M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARQT and 13F data
ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARQT
- MONTANOVA CAPITAL, LLC 12.44M sh · $326.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.87M sh · $258.91M · Q2 2026
- Rubric Capital Management LP 8.27M sh · $216.88M · Q2 2026
- ORBIMED ADVISORS LLC 2.04M sh · $53.54M · Q2 2026
- OBERWEIS ASSET MANAGEMENT INC/ 1.37M sh · $36.00M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.27M sh · $33.18M · Q2 2026
- Jones Hill Capital LP 1.09M sh · $28.57M · Q2 2026
- FISHMAN JAY A LTD/MI 595.00K sh · $15.60M · Q2 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held ARQT?
Cormorant Asset Management, LP has disclosed ARQT holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is Cormorant Asset Management, LP's current position in ARQT?
As of Q2 2026, Cormorant Asset Management, LP holds 175.00K shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $4.59M, representing 0.24% of its reported portfolio and ranking #40.
Has Cormorant Asset Management, LP been buying or selling ARQT?
In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in ARQT. The position peaked in Q4 2024 at 1.82M shares.
Which other funds hold ARQT?
Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.